The 1st released US patent.
BioSante receives two new US patents covering 2A/Furin technology for expressing proteins BioSante Pharmaceuticals, Inc. today announced the receipt of two US brand-new patents directed to its 2A/Furin technology for expressing proteins. The 1st released US patent, US Pat. No., 7,709,224, covers options for production recombinant antibodies. By incorporating our 2A/Furin technology into antibody-expression in viral vectors you’ll be able to rapidly generate steady, high creating antibody cell lines. The next cell lines may help reduce enough time and lower the expense of commercial antibody production. The second released US patent, US Pat. No. 7,714,199 covers extra adeno-linked virus vectors including the 2A/furin technology and options for expressing antibodies in vivo using these vectors and builds on currently released patents covering vectors and options for creating antibodies in vivo and in vitro.It is has been evaluated primarily in combination with chemotherapy,11,12 but also as monotherapy. The approval allowed for the use of cetuximab with irinotecan in the further and second lines of mCRC 2009 US Label amended to prevent the use of Erbitux® in individuals whose tumors possess KRAS mutations in codon 12 or 13 2010 Japan Approved as a first-line treatment, in combination with chemotherapy, for sufferers with EGFR-expressing, curatively unresectable , advanced or recurrent mCRC carrying the KRAS wild-type gene 5EU = five European markets CRC = colorectal malignancy; EGFR = epidermal growth aspect receptor; mCRC = metastatic colorectal cancer..